Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 62 Glioblastoma 52 Lung Neoplasms 49 Breast Neoplasms 46 Prostatic Neoplasms 39 Head and Neck Neoplasms 38 Squamous Cell Carcinoma of Head and Neck 33 Esophageal Neoplasms 30 Brain Neoplasms 28 Lymphoma 27 Gliosarcoma 27 Rectal Neoplasms 24 Hodgkin Disease 24 Pancreatic Neoplasms 22 Adenocarcinoma Of Esophagus 22 Central Nervous System Neoplasms 21 Precursor Cell Lymphoblastic Leukemia-Lymphoma 20 Neoplasms 20 Lymphoma, Non-Hodgkin 17 Leukemia 17 Glioma 17 Burkitt Lymphoma 16 Sarcoma 15 Lymphoma, Large B-Cell, Diffuse 15 Lymphoma, Follicular 14 Carcinoma, Squamous Cell 14 Colorectal Neoplasms 13 Astrocytoma 13 Neoplasm Metastasis 12 Melanoma 12

Interventions

Gemcitabine 4 Cisplatin 4 Carboplatin 3 pembrolizumab 2 erdafitinib 2 durvalumab 2 vinflunine 1 tremelimumab 1 enfortumab vedotin 1 avelumab 1 Sunitinib 1 Radiotherapy 1 Paclitaxel 1 Nivolumab 1 Midazolam 1 Metformin 1 Ipilimumab 1 Docetaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Urothelial Cancer × Radiotherapy × Clear all

NCT02891161 2024-11-27

DUART

Big Ten Cancer Research Consortium

Phase 1/2 Terminated

26 enrolled 20 charts

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡